Lexicon Pharmaceuticals Company Profile (NASDAQ:LXRX)

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its quarterly earnings results on Tuesday, August, 1st. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.12. The business earned $12 million during the quarter, compared to analyst estimates of $18.34 million. Lexicon Pharmaceuticals had a negative net margin of 170.63% and a negative return on equity of 94.87%. The company's revenue was down 40.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.37) earnings per share. View Lexicon Pharmaceuticals' Earnings History.

Lexicon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, October, 30th 2017. View Earnings Estimates for Lexicon Pharmaceuticals.

4 brokers have issued twelve-month price targets for Lexicon Pharmaceuticals' stock. Their predictions range from $21.00 to $39.00. On average, they expect Lexicon Pharmaceuticals' stock price to reach $28.75 in the next twelve months. View Analyst Ratings for Lexicon Pharmaceuticals.

Here are some recent quotes from research analysts about Lexicon Pharmaceuticals stock:

• 1. Cowen and Company analysts commented, "Xermelo’s US launch is off to a solid start with 2Q sales of $3.6MM just ahead of." (8/1/2017)
• 2. According to Zacks Investment Research, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. " (7/18/2017)
• 3. Wedbush analysts commented, "Even with FDA approval of LXRX's lead drug achieved, we still see several clinical and regulatory catalysts for LXRX over the coming months that could lift shares."In addition to the launch of XERMELO, we see several catalysts for LXRX, including data presentations of the InTandem 1&2 results at ADA (June 9-13, San Diego), release of 52-week pivotal extension results from InTandem 1, 2 and 3 in Mid:17, and potential early indication that the FDA may consider reviewing sotagliflozin for T1D alone in Q3:17," (3/1/2017)
• 4. Needham & Company LLC analysts commented, "Lexicon and FDA announced approval of Xermelo (telotristat) yesterday for treatment of Carcinoid Syndrome. Label appears favorable w/ no contraindications and only constipation as a warning/ precaution. Mgmt guided for availability at specialty pharmacies 3/6/17. WAC pricing set at $5,164/ 28 days (~67,000/ yr), in-line w/ prior mgmt guidance (i.e. comparable to somatostatin analogs). We estimate U.S. peak sales ~$300M (unch). Pt population is well defined due to availability of somatostatin analogs and we believe Lexicon can penetrate market reasonably quickly. Lexicon hired ~50 sales reps, consistent w/ prior guidance. They will begin visiting physicians 3/2/17. Near-term milestones for Lexicon include update on sotagliflozin NDA submission strategy/ timing in Type 1 Diabetes. We assume YE17. Reiterate BUY." (3/1/2017)

Some companies that are related to Lexicon Pharmaceuticals include AveXis (AVXS), Juno Therapeutics (JUNO), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), Intercept Pharmaceuticals (ICPT), GW Pharmaceuticals PLC (GWPH), Ultragenyx Pharmaceutical (RARE), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Sarepta Therapeutics (SRPT), Axovant Sciences (AXON), Prothena Corporation PLC (PRTA), Aerie Pharmaceuticals (AERI), Loxo Oncology (LOXO), NovoCure Limited (NVCR), Halozyme Therapeutics (HALO), Radius Health (RDUS) and Array BioPharma (ARRY).

Lexicon Pharmaceuticals' management team includes the folowing people:

• Raymond Debbane, Independent Chairman of the Board
• Lonnel Coats, President, Chief Executive Officer, Director
• Jeffrey L. Wade J.D., Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs
• Pablo Lapuerta M.D., Executive Vice President, Chief Medical Officer
• Alan J. Main Ph.D., Executive Vice President - CMC and Supply Operations
• Alexander A. Santini, Executive Vice President, Chief Commercial Officer
• Praveen Tyle Ph.D., Executive Vice President - Research and Development
• James F. Tessmer, Vice President - Finance & Accounting
• Philippe J. Amouyal, Independent Director
• Samuel L. Barker Ph.D., Independent Director

Lexicon Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Artal Group S.A. (54.48%), FMR LLC (14.95%), Ulys L.L.C. (4.09%), Vanguard Group Inc. (3.51%), USS Investment Management Ltd (3.32%) and Eagle Asset Management Inc. (2.71%). View Institutional Ownership Trends for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Teachers Retirement System of The State of Kentucky, Alliancebernstein L.P., GSA Capital Partners LLP, Virginia Retirement Systems ET AL, TIAA CREF Investment Management LLC, Bank of Montreal Can and Bank of New York Mellon Corp. View Insider Buying and Selling for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including USS Investment Management Ltd, Pinnacle Associates Ltd., State Street Corp, Voya Investment Management LLC, DekaBank Deutsche Girozentrale, Quantitative Investment Management LLC, FMR LLC and OxFORD Asset Management LLP. View Insider Buying and Selling for Lexicon Pharmaceuticals.

Shares of Lexicon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Lexicon Pharmaceuticals stock can currently be purchased for approximately $14.00.